SCHEMBL365630

SCHEMBL365630

CCc1[c]cccc1-c1ccccc1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HEXA P06865 1/20 0.36
HEXB P07686 1/20 0.36
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
TSHR P16473 2/20 0.33
ACHE P22303 1/20 0.33
BRD4 O60885 1/20 0.33
HTR7 P34969 2/20 0.32
ALDH1A1 P00352 2/20 0.32
PKM P14618 1/20 0.32
NOTUM Q6P988 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8974022 0.85 CNR1 (0.34)
SCHEMBL11877248 0.82 TLR8 (0.34) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL1592694 0.82 ELANE (0.34) TSHRGAAHPGD
SCHEMBL7458208 0.81 HEXA (0.34) HEXAHEXBNPC1RAB9ASMN1; SMN2
SCHEMBL216731 0.81
SCHEMBL456469 0.81 CYP2D6 (0.40) NPC1RAB9ASMN1; SMN2ALDH1A1CYP2D6
SCHEMBL6048330 0.80 POLB (0.31)
SCHEMBL29228990 0.79 TSHR (0.33) TSHRACHE
SCHEMBL15636515 0.79 DPP4 (0.40) NPC1RAB9ASMN1; SMN2TSHRHTR7
SCHEMBL1774729 0.78 DPP4 (0.36) RAB9ASMN1; SMN2HTR7ALDH1A1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012007007-A1 INHIBITORS OF HDME EPITHERAPEUTICS APS (DK) 2012-01-19 WO claimed
US-11720020-B2 Resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-08-08 US disclosed
US-20210063879-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2021-03-04 US disclosed
WO-2012007007-A1 INHIBITORS OF HDME EPITHERAPEUTICS APS (DK) 2012-01-19 WO disclosed
US-6498182-B2 BENZO(G)INDOLE -2,5(3H)-DIONE AND -2-ONE DERIVATIVE ANTIDIABETIC AGENTS BIOVITRUM AB (SE) 2002-12-24 US disclosed
US-20020061921-A1 Novel compounds BIOVITRUM AB (SE) 2002-05-23 US disclosed
WO-2002026707-A1 NOVEL COMPOUNDS BIOVITRUM AB (SE) 2002-04-04 WO disclosed
WO-1993024468-A1 PYRIMIDINYL- AND TRIAZINYL- SALICYL- AND PICOLYLAMIDES AND THE USE, AS HERBICIDES, AND PREPARATION THEREOF CIBA-GEIGY AG (CH) 1993-12-09 WO disclosed
US-4381360-A 1,3-Dicarbonyl compounds and polyvinyl halide resin compositions containing the same PHOENIX CHEMICAL CORPORATION (US) 1983-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061921-A1 Novel compounds GPR119, IAPP, GLP1R HEXA 3005/4885HEXB 2253/4885NPC1 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.